Nausea & Appetite
Cannabis has one of its longest established medical uses in the management of chemotherapy-induced nausea and vomiting (CINV) and appetite stimulation, with synthetic THC medications approved since the 1980s.
Quick Reference
Approved Medications
Two THC-based medications have been approved for nausea and appetite: Dronabinol (synthetic THC, brand name Marinol) was approved by the FDA in 1985 for CINV and in 1992 for HIV-related anorexia. Nabilone (synthetic THC analogue, brand name Cesamet) is approved in multiple countries for CINV. These represent some of the first medically approved cannabis-derived drugs and have decades of clinical use data. Nabiximols (Sativex) is also used off-label for nausea management in some cancer patients.
How THC Reduces Nausea
THC acts on CB1 receptors in the dorsal vagal complex of the brainstem — a key area controlling the vomiting reflex. CB1 receptor activation in this area suppresses the emetic reflex and reduces nausea perception. THC also acts on serotonin 5-HT3 receptors in the gut, which mediate chemotherapy-induced nausea. This dual mechanism makes THC particularly effective for chemotherapy-induced nausea which is often refractory to conventional antiemetics.
Appetite Stimulation
THC stimulates appetite through CB1 receptors in the hypothalamus, increasing ghrelin (the hunger hormone) and enhancing the hedonic value of food. This "munchies" effect has genuine medical applications for cachexia (severe weight loss) in cancer and HIV/AIDS patients, anorexia nervosa, and other wasting conditions. Clinical trials show dronabinol significantly increases appetite and maintains body weight in HIV wasting syndrome patients.
Practical Use for CINV
For chemotherapy-induced nausea, cannabis is most useful as an adjunct to conventional antiemetics rather than a replacement. Oral preparations are difficult when nausea is severe — inhalation or sublingual preparations are often more practical. Prophylactic use (taking before chemotherapy) is more effective than reactive dosing. A low-dose THC preparation (2.5–5mg) is typically appropriate, titrated based on response. Always discuss with your oncologist and pharmacist before adding cannabis to a chemotherapy regimen.